Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01558661 · ClinicalTrials.gov registry record · Phase 2
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
A Phase 2 study of Adenoid Cystic Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01558661 is a Phase 2 study of Adenoid Cystic Carcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 33 participants, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01558661, a Phase 2 study of Adenoid Cystic Carcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out what effects, good and/or bad, a new treatment called axitinib has on the patient and adenoid cystic carcinoma. This type of cancer study is called a phase II study. Axitinib is an oral medication that can interfere with cancer cell growth and reduce the growth of blood vessels around tumors. This study will help find out if axitinib is a useful drug for treating patients with adenoid cystic carcinomas. Axitinib is an experimental drug that has not yet been approved by the Food and Drug Administration for use in adenoid cystic carcinoma.
Conditions Studied
Interventions
- DRUG AG-013736 (AXITINIB)
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-03 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01558661
The ClinicalTrials.gov registry entry for NCT01558661 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (74% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which AG-013736 (AXITINIB) is the first listed.
NCT01558661 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01558661 about?
NCT01558661 is a clinical study titled "Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma". The purpose of this study is to find out what effects, good and/or bad, a new treatment called axitinib has on the patient and adenoid cystic carcinoma. This type of cancer study is called a phase II study. Axitinib is an oral medication that can interfere with cancer cell growth and reduce the gro...
What is the current status of trial NCT01558661?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2012-03. Estimated completion is 2016-08.
What conditions does trial NCT01558661 study?
This clinical trial studies the following conditions: Adenoid Cystic Carcinoma.
What interventions are being tested in trial NCT01558661?
The interventions under investigation include: AG-013736 (AXITINIB) (DRUG).
Who is sponsoring clinical trial NCT01558661?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01558661 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
RECRUITING · Phase 2
-
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.